Ross Moat Net Worth

The estimated Net Worth of Ross Moat is at least $2.2 millió dollars as of 15 July 2024. Ross Moat owns over 73,589 units of Kiniksa Pharmaceuticals International Plc stock worth over $2,196,490 and over the last 3 years Ross sold KNSA stock worth over $0.

Ross Moat KNSA stock SEC Form 4 insiders trading

Ross has made over 9 trades of the Kiniksa Pharmaceuticals International Plc stock since 2021, according to the Form 4 filled with the SEC. Most recently Ross exercised 73,589 units of KNSA stock worth $749,872 on 15 July 2024.

The largest trade Ross's ever made was exercising 73,589 units of Kiniksa Pharmaceuticals International Plc stock on 15 July 2024 worth over $749,872. On average, Ross trades about 7,585 units every 91 days since 2021. As of 15 July 2024 Ross still owns at least 90,242 units of Kiniksa Pharmaceuticals International Plc stock.

You can see the complete history of Ross Moat stock trades at the bottom of the page.

What's Ross Moat's mailing address?

Ross's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.

Insiders trading at Kiniksa Pharmaceuticals International Plc

Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... és Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.

What does Kiniksa Pharmaceuticals International Plc do?

Complete history of Ross Moat stock trades at Kiniksa Pharmaceuticals International Plc

Kiniksa Pharmaceuticals International Plc executives and stock owners

Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:

• Sanjiv Patel,
  Chairman of the Board, Chief Executive Officer
• John Paolini,
  Senior Vice President and Chief Medical Officer
• Qasim Rizvi,
  Senior Vice President - Operations, Chief Commercial Officer
• Sanj K. Patel,
  CEO & Chairman
• Richard Levy,
  Independent Director
• Felix Baker,
  Lead Independent Director
• Thomas Malley,
  Independent Director
• Barry Quart,
  Independent Director
• Stephen Biggar,
  Independent Director
• Tracey McCain,
  Independent Director
• Kimberly Popovits,
  Independent Director
• G. Bradley Cole,
  Director
• Thomas Beetham,
  Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary
• Michael Megna,
  Principal Financial Officer, Chief Accounting Officer
• Dr. John F. Paolini,
  Sr. VP & Chief Medical Officer
• Mei Jang,
  VP of Technical Operations
• Michael R. Megna,
  Chief Accounting Officer & VP of Fin.
• Christine Maurer,
  Sr. VP of Program Management
• Carsten Boess,
  Exec. VP of Corp. Affairs
• Rasmus Holm-Jorgensen,
  Sr. VP, Chief Strategy & Portfolio Officer
• Melissa Manno,
  Chief HR Officer
• Madelyn Zeylikman,
  Gen. Counsel
• Chad Morin,
  VP & Chief Compliance Officer
• Mark Ragosa C.F.A.,
  Sr. VP & CFO
• Bros. Advisors Lp667, L.P.B...,
  
• Asset Management, Lp Chen B...,
  
• Stephen F. Mahoney,
  President & COO
• James E Deerfield Mgmt L.P....,
  
• Carsten Boess,
  10% owner
• Chris Heberlig,
  EVP & CFO
• Sanj K Patel,
  CHAIRMAN & CEO
• Ross Moat,
  CHIEF COMMERCIAL OFFICER
• Mark Ragosa,
  CHIEF FINANCIAL OFFICER
• Eben Tessari,
  CHIEF OPERATING OFFICER
• Arian Pano,
  Chief Clinical Dev. Officer